Fig 3 - available via license: CC BY-NC
Content may be subject to copyright.
Radiolucent lesion with ill-defined margins at right body/angle mandible had extended anteriorly to the premolar region and posteriorly to the mid-ramus. The inferior dental canal is enlarged.
Source publication
A 57-year-old male with follicular lymphoma of mandible presented with clinical and radiographic features suggestive of osteomyelitis. He was treated for his ‘infection’ over three years. Several biopsies taken from early 2007 to 2009 reported negative for malignancy. Radiographic findings over the same period showed diffuse radiolucent area at the...
Context in source publication
Context 1
... orthopantomograph taken on 2 March 2010 (see Fig. 3) showed the diffuse radiolucent area at the right body/angle of the mandible had extended anteriorly to the premolars region and posteriorly to his mid-ramus. The lesion had ill-defined borders. The inferior dental canal was enlarged. cLINIcAL PROGREss A tentative diagnosis of chronic osteomyelitis was made and a biopsy was scheduled ...
Similar publications
[This corrects the article DOI: 10.3389/fgene.2023.1066808.].
Objectives: Emerging evidence suggests that microRNAs could serve as non-invasive biomarkers for cancer patients. However, they are mostly not fully investigated as biomarkers in the classification, progression and prognosis of different cancers. Our study was designed to explore the microRNA-155 (miR-155) expression levels in peripheral blood mono...
Obinutuzumab is a glycoengineered tumor-targeting anti-CD20 mAb with a modified crystallizable fragment (Fc) domain designed to increase the affinity for the FcγRIIIA/CD16 receptor, which was recently approved for clinical use in CLL and follicular lymphoma. Here we extend our previous observation that, in human NK cells, the sustained CD16 ligatio...
Background
Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) being the most common subtypes. Standard frontline therapy consists of immunochemotherapy with a CD20 monoclonal antibody (mAb), such as rituximab, delivered in combination with multi-age...
